The reversal of low-molecular-weight heparins, particularly at supratherapeutic levels, remains challenging. The paucity of literature available to guide the treatment of these patients makes their management difficult for primary care providers, surgeons, and subspecialists alike. We report the case of a 34-year-old woman, who intentionally overdosed on enoxaparin (Lovenox) in a suicide attempt. Her initial antifactor Xa activity level was 8.3 IU/ml, the highest level reported in the literature to date. She was initially managed conservatively, however, within 24 h of admission she developed evidence of acute blood loss. Protamine sulfate and three doses of recombinant activated factor VII (rFVIIa) were administered in an effort to control bleeding. We report the effects of these measures and review the literature to date. Our study is one of the first to graph in-vivo antifactor Xa activity levels and to suggest a drug half 
Introduction
Low-molecular-weight heparins (LMWH) are routinely used for the treatment and prophylaxis of venous thromboembolism (VTE). There are several advantages to their use including weight-based dosing and few drug and dietary interactions leading to stable dosing. One drawback, however, is that the reversal of LMWH can be challenging in the setting of bleeding or the need for emergent surgery.
Case report
A 34-year-old Caucasian woman was brought to the emergency department (ED) for a suicide attempt involving the self-injection of 1600 mg of enoxaparin (20 syringes of 80 mg). After the injection, she slit her wrists and hanged herself. She is heterozygous for the factor V Leiden mutation and had a pulmonary embolus 2.5 years prior to this admission. She had been prescribed enoxaparin 1 mg/kg (80 mg) Q 12 h by her primary provider.
In the ED, central venous access was attempted in her bilateral femoral veins. An initial antifactor Xa activity level was 8.3 IU/ml (therapeutic range 0.5-1.1 IU/ml for twice daily dosing, 1.0-2.0 IU/ml for once daily dosing), which was measured via serial dilutions. Partial thromboplastin time (PTT) on admission was 98 s (23-38 s). Initial hemoglobin and hematocrit were 12.6 g/dl (12-16 g/dl) and 38.1% (35-45%), respectively. Apart from mild oozing from her wrists and intraosseous access site, she had no clinical evidence of bleeding. She was admitted to the medical ICU for close observation. Her PTT peaked 6 h after admission at 169 s.
Serial antifactor Xa activity levels and PTT values are shown (Figs 1 and 2).
Our initial management was supportive as the patient was clinically stable and without evidence of bleeding. After approximately 15 h, serial complete blood counts had revealed a drop in her hematocrit to 28.8% and she was transfused two units of packed red blood cells. A repeat hematocrit 3 h later was 22.7% necessitating the transfusion of two additional units (Fig. 3) . Computed tomography (CT) of the abdomen and pelvis showed bilateral retroperitoneal hematomas.
Given active bleeding, the decision was made to administer protamine sulfate 50 mg IV (25 h after admission). Three doses of rFVIIa, 45 mg/kg, were also administered at 24, 26, and 28 h with the effects on antifactor Xa activity and PTT shown (Figs 1 and 2 ).
Despite factor V Leiden heterozygosity, no thrombotic complications were seen after rFVIIa administration. By hospital day number five, the patient's antifactor Xa activity level had fallen to subtherapeutic levels.
Discussion
Antithrombin III (AT-III) circulates naturally at high concentrations in the blood stream albeit in a poorly reactive conformation. Through interactions with the pentasaccharide sequence found in unfractionated heparin, AT-III becomes an efficient inhibitor of coagulation at the levels of factors IXa, Xa, and thrombin. Smaller heparin fragments, such as those in LMWHs, are also effective antithrombotic agents. LMWHs accelerate the inhibitory rate of AT-III on factors IXa and Xa but have a lesser effect on the inhibition of thrombin. Protamine sulfate primarily works to reverse the effects of anticoagulation by the inhibition of the heparin-AT-III complex. There is little effect on antifactor Xa activity, and thus LMWHs are only partially reversed.
With LMWHs, the PTT correlates poorly with antifactor Xa activity. This is because the primary effect of LMWHs is through the potentiation of AT-III mediated inhibition of factor Xa. Thus, the PTT is often normal or only minimally prolonged at therapeutic LMWH doses. For this reason, the antifactor Xa activity level is the preferred method to monitor LMWHs. This phenomenon is illustrated in our case in which, 24 h after admission, our patient's PTT had fallen to within the normal range whereas her anti-Xa activity level remained markedly elevated (Figs 1 and 2 ).
The elevation in the PTT at supratherapeutic LMWH doses illustrates that although the LMWHs are predominantly shorter chain polysaccharides, some larger chain molecules are also present in these preparations. These larger molecules, similar to those found in unfractioned heparin, potentiate the AT-III-mediated inhibition of thrombin and thus prolong the PTT. At supratherapeutic doses, the effect on the PTT becomes apparent, as there are more large chain molecules to inhibit thrombin through interactions with AT-III.
Over the last several years, there have been multiple case reports of patients requiring reversal of LMWH for a variety of reasons ranging from life-threatening bleeding to the need for emergency surgery. Efforts to develop an antidote or other means to reverse LMWH have been limited.
The American College of Chest Physicians (ACCP) recommendations for the treatment of LMWH overdose are consistent with the manufacturer's instructions. If reversal is sought within 8 h of LMWH administration, their guidelines recommend protamine 1 mg/100 antifactor Xa units followed by a second dose of 0.5 mg protamine/100 antifactor Xa units if clinically indicated. Smaller doses may be considered in patients more than 8 h out from injection [1] . The maximum recommended single dose of protamine sulfate is 50 mg, which would be ineffective in large overdoses such as in our patient. Higher doses may lead to untoward effects including anaphylactic reactions and hemorrhage [2] .
In animal models, the administration of protamine sulfate has shown reductions in blood loss. The effects of the anticoagulant, however, were still evident suggesting only an incomplete reversal [3] .
Reports of using protamine sulfate for the reversal of LMWH in humans have yielded similar results. Patients with supratherapeutic antifactor Xa activity levels have had ongoing bleeding despite protamine administration, suggesting a limited benefit. A patient with perioperative renal failure and hemorrhage who was treated with protamine had only minimal improvement in her antifactor Xa activity level from 1.65 to 1.34 IU/ml and continued to have clinical evidence of bleeding (described as continued transfusion requirements) [4] . Partial reversal was also noted in a patient with subdural hemorrhage with an
Reversal of low-molecular-weight heparins Byrne and Zumberg 773 PTT vs. time. Protamine sulfate was administered at 25 h (solid arrow). rFVIIa was administered at 24, 26, and 28 h (hash marks). antifactor Xa activity level of 1.02 IU/ml. He received a total of three doses of protamine (60 mg) with less than a 50% reduction in antifactor Xa activity and concurrent clinical deterioration suggestive of continued bleeding [5] .
A cohort of 18 patients from the United Kingdom requiring LMWH reversal due to bleeding or emergency surgery reported clinical benefit in a subset of patients with antifactor Xa activity levels less than 1 IU/ml. These patients had clinical resolution of their bleeding following the administration of protamine sulfate. Six received only one dose whereas two received a subsequent dose.
Of the four patients, who had antifactor Xa activity levels greater than 1.0 IU/ml, two had persistent bleeding despite repeated doses of protamine [6] .
Protamine sulfate was administered in the setting of a 10-fold overdose in a 4 kg infant, which resulted in an antifactor Xa activity level greater than 3 IU/ml. She was treated with protamine 35 mg IV over the course of 7.5 h with improvement of her antifactor Xa activity level.
There was no clinically significant bleeding described [7] . When plotted, the antifactor Xa activity levels followed nonlinear pharmacokinetics with a pattern similar to that of our patient.
Due to incomplete reversal with protamine, rFVIIa has been used in a small number of patients. Three patients, all with known underlying hypercoagulable disorders, developed bleeding while on LMWH. In all three cases, the patients were treated with rFVIIa with reported improvement of bleeding. No patient suffered a thrombotic event [8] .
Others have conservatively managed patients with supratherapeutic antifactor Xa activity levels without the use of protamine or rFVIIa including a patient with the previously highest antifactor Xa activity level reported to date. This patient presented with an antifactor Xa activity level of 6.2 IU/ml and was managed with observation alone. Pharmacokinetics, as a function of antifactor Xa activity, followed a linear trajectory but few data points were noted. A second patient was also safely observed without evidence of bleeding [9] .
Conclusion
Although protamine sulfate and rFVIIa have both been cited as options in the treatment of LMWH overdose, the data suggests only partial reversal. Our patient with a markedly elevated antifactor Xa activity level and PTT had only minimal improvement from these interventions. ACCP guidelines currently recommend treatment with protamine sulfate if clinically indicated. More studies are needed to further evaluate treatment of overdoses of LMWHs as well as newly developed anticoagulants.
